Equity Overview
Price & Market Data
Price: $1.10
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $61,824,248
Volume: 0
Performance Metrics
1 Week: 9.51%
1 Month: 24.05%
3 Months: 57.28%
6 Months: 14.76%
1 Year: -70.80%
YTD: -14.12%
Company Details
Employees: 131
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.